Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-03-27

Clinical Trial Update: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating octreotide LAR to prevent chemotherapy-induced diarrhea has completed; results were posted on 2012-03-27.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sandostatin LAR (octreotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chemotherapy-induced Diarrhea | Phase 3 | Status: COMPLETED | Results posted: 2012-03-27